UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
| |
| |
| (Commission File Number) |
(I.R.S. Employer Identification No.) |
| |
| |
| (Address of principal executive offices) |
(Zip Code) |
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| |
|
| ||
| | ||||
| |
|
| ||
| |
|
| ||
| |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. |
On October 31, 2019, Baxter International Inc. (“Baxter” or the “Company”) entered into Amendment No. 2 to its existing $1.5 billion, five-year revolving credit agreement, dated as of July 1, 2015, as amended, with JPMorgan Chase Bank, National Association, as Administrative Agent, and the various lenders thereto (the “USD Credit Agreement”). The amendment provides an extension of the required delivery date for the Company’s quarterly financial statements (with respect to the fiscal quarter ended September 30, 2019) to December 31, 2019. The lenders under the USD Credit Agreement also provided a waiver (through December 31, 2019) of any unmatured event of default or event of default in the USD Credit Agreement that may directly arise out of, or directly relate to, certain matters disclosed in the Company’s Form 8-K’s filed on October 24, 2019.
Additionally, on the same date, the Company entered into Amendment No. 1 to its guaranty (the “Guaranty”) of the Baxter Healthcare SA’s and Baxter World Trade SPRL’s existing €200 million, five-year revolving credit agreement, dated as of July 1, 2015, as amended, with J.P. Morgan Europe Limited, as Administrative Agent, and the various lenders thereto (the “Euro Credit Agreement”). The amendment to the Guaranty provides the same extension of the required delivery date for the Company’s quarterly financial statements (with respect to the fiscal quarter ended September 30, 2019) to December 31, 2019. The lenders under the Euro Credit Agreement also provided a waiver (through December 31, 2019) of any unmatured event of default or event of default in the Euro Credit Agreement or the Guaranty that may directly arise out of, or directly relate to, certain matters disclosed in the Company’s Form 8-K’s filed on October 24, 2019.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 6, 2019
| BAXTER INTERNATIONAL INC. | ||
| /s/ Ellen K. McIntosh | ||
| By: |
Ellen K. McIntosh | |
| Senior Vice President, Associate General Counsel and Corporate Secretary | ||